Straits Times Index
3,349.29 +12.70 (+0.38%) Nikkei
38,820.86 +332.96 (+0.87%) Hang Seng
18,475.57 +395.96 (+2.19%) FTSE 100
8,275.38 +44.33 (+0.54%) BTC-USD
68,467.38 +728.30 (+1.08%) CMC Crypto 200
1,476.03 +47.46 (+3.32%)
VRNA Dec 2024 25.000 call
| Previous close | 3.3000 |
| Open | N/A |
| Bid | 0.1000 |
| Ask | 1.8000 |
| Strike | 25.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.3000 - 3.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
- GuruFocus.com
Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview
Insights into Verona Pharma's First Quarter Performance and Future Prospects
Insider MonkeyVerona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript May 9, 2024 Verona Pharma plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to Verona Pharma’s First Quarter 2024 Financial Results and Operating Highlights Conference Call. At […]
GlobeNewswireVerona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and prov
